Finance

Lists
Outlook: 47.4% bullish·0.0% bearish
Go to analysis
TMO:NYSE
Thermo Fisher Scientific Inc
$675.00
-0.50%
(-3.39) 1D
Sep 25, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMO...
Open
$677.53
High
$678.00
Low
$664.53
Mkt. cap
249.58B
Avg. vol.
1.99M
Volume
101.00
Dividend
0.28%
Quarterly dividend
$0.47
Ex-dividend date
Jun 15, 2026
P/E ratio
36.34
52-wk high
$682.98
52-wk low
$435.27
EPS
$18.58
Beta
0.85
Shares outstanding
369.75M
No. of employees
125K
Open
$677.53
High
$678.00
Low
$664.53
Mkt. cap
249.58B
Avg. vol.
1.99M
Volume
101.00
Dividend
0.28%
Quarterly dividend
$0.47
Ex-dividend date
Jun 15, 2026
P/E ratio
36.34
52-wk high
$682.98
52-wk low
$435.27
EPS
$18.58
Beta
0.85
Shares outstanding
369.75M
No. of employees
125K
News stories
From web sources and news partners
About Thermo Fisher Scientific Inc
CEO-
Employees125K
Founded1956
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websitethermofisher.com
Analyst ratings
Based on 19 analysts giving stock ratings to TMO in the past 3 months
Strong buy
Buy
16
Hold
3
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for TMO in the last 3 months.
Highest
Current $675.00
$780.00 (+15.56%)
Average
$658.71 (-2.41%)
Lowest
$570.00 (-15.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eve Burstein
Bernstein
Hold
Maintained
$575.00
-14.8%
09/25/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
$720.00
+6.7%
09/25/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$780.00
+15.6%
09/20/2026
Evan Stampler
Wells Fargo
Buy
Reiterated
$660.00
-2.2%
09/17/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
-
-
09/15/2026
Unknown Analyst
UBS
Buy
Upgraded
$730.00
+8.1%
09/08/2026
Doug Schenkel
UBS
Buy
Initiated
$730.00
+8.1%
09/08/2026
Michael Luo CFA
CLSA
Buy
Initiated
$748.00
+10.8%
09/03/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$690.00
+2.2%
07/28/2026
Jill Wu
CMB International Securities
Buy
Maintained
$660.00
-2.2%
07/27/2026
David Westenberg
Piper Sandler
Hold
Maintained
$600.00
-11.1%
07/27/2026
Aristotelis Moutopoulos
DZ BANK AG
Buy
Maintained
$630.00
-6.7%
07/27/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$650.00
-3.7%
07/24/2026
Dan Leonard
RBC Capital
Hold
Maintained
$580.00
-14.1%
07/23/2026
Luke Sergott
Barclays
Buy
Maintained
$650.00
-3.7%
07/24/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/24/2026
Daniel Brennan
TD Cowen
Buy
Maintained
$675.00
0%
07/23/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
$650.00
-3.7%
07/23/2026
Tycho Peterson
Jefferies
Buy
Reiterated
$630.00
-6.7%
07/23/2026
Brandon Couillard
Wells Fargo
Buy
Reiterated
$615.00
-8.9%
07/23/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$570.00
-15.6%
07/06/2026
Sidharth Sahoo
HSBC
Hold
Downgraded
$540.00
-20%
06/03/2026
Michael Polark
Wolfe Research
Buy
Initiated
$535.00
-20.7%
06/01/2026
Unknown Analyst
Jefferies
Buy
Maintained
$585.00
-13.3%
05/21/2026
Unknown Analyst
RBC Capital
Hold
Initiated
$490.00
-27.4%
05/14/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Bill Selesky
Argus Research
Buy
Maintained
$560.00
-17%
04/30/2026
Unknown Analyst
Argus Research
Buy
Maintained
$560.00
-17%
04/30/2026
David Toung
Argus Research
Buy
Maintained
$560.00
-17%
04/30/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$639.00
-5.3%
04/24/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Maintained
$620.00
-8.1%
04/17/2026
Patrick B Donnelly
Citi
Buy
Maintained
$685.00
+1.5%
04/06/2026
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$6.03 / $5.71
+5.60%beat
Revenue / Est. (USD)
11.99B / 11.70B
+2.50%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.12B
12.22B
11.00B
11.99B
Cost of goods sold
6.53B
7.17B
6.56B
7.08B
Cost of revenue
6.53B
7.17B
6.56B
7.08B
Research and development expenses
346.00M
356.00M
336.00M
364.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.10B
2.24B
2.14B
2.30B
Operating expense
2.45B
2.46B
2.48B
2.66B
Total operating expenses
8.98B
9.63B
9.04B
9.74B
Operating income
2.14B
2.59B
1.97B
2.25B
Other non operating income
-32.00M
-32.00M
-15.00M
13.00M
EBT including unusual items
1.83B
2.12B
1.73B
1.91B
EBT excluding unusual items
2.03B
2.44B
1.83B
2.05B
Income tax expense
207.00M
153.00M
70.00M
167.00M
Effective tax rate
11.32%
7.21%
4.06%
8.75%
Other operating expenses
-
-135.00M
1.00M
-
Net income
1.62B
1.96B
1.65B
1.74B
Net profit margin
14.53%
16.08%
15.00%
14.47%
Earnings per share
5.79
6.57
5.44
6.03
Interest and investment income
234.00M
258.00M
233.00M
207.00M
Interest expense
-347.00M
-365.00M
-354.00M
-401.00M
Net interest expenses
-113.00M
-107.00M
-121.00M
-194.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.82B
3.31B
2.70B
3.07B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps